PROSPER RCC (study EA8143) is an innovative phase 3 clinical trial that may lead to better survival for patients with renal cell carcinoma (RCC), a type of kidney cancer. The study seeks to determine whether treatment with an immune system therapy, nivolumab, before and after surgery to remove a kidney tumor may reduce the likelihood of the cancer returning.
Nine out of 10 people who get kidney cancer get renal cell cancer. Currently, the standard treatment is to remove the kidney or part of the kidney by surgery and then follow with observation. Doctors use scans and exams to watch for signs of the cancer returning. Unfortunately, renal cell cancer does come back in a considerable number of patients – and when this happens the cancer is much harder to treat or cure.
Led by Mohamad Allaf, MD of Johns Hopkins University, the PROSPER RCC trial aims to prevent recurrence by giving patients one dose of nivolumab prior to surgery and then several doses after surgery. Nivolumab works by stimulating the body’s immune system to help the body fight cancer. Patients receive the drug through the veins (intravenous).
This strategy of treating cancer prior to surgery with immune system therapy has proven effective in other types of cancer, such as bladder, breast, and lung.
“PROSPER RCC is one of the most unique trials out there now for patients with kidney cancer,” says Michael Carducci, MD (Johns Hopkins), another physician involved with the study and chair of ECOG-ACRIN’s Genitourinary Cancer Committee. “It takes a novel approach by giving a dose of nivolumab before surgery, when the tumor is still in place and the immune cells can closely interact with both the drug and the cancer cells and begin to respond; when surgery is done we give the patient nivolumab again to help the immune system find and destroy any remaining cancer cells, and evaluate for cures and recurrence-free survival.”
Learn more about PROSPER RCC, currently enrolling patients in the United States, Canada, and Israel.